GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » aTyr Pharma Inc (NAS:LIFE) » Definitions » Net Change in Cash

aTyr Pharma (aTyr Pharma) Net Change in Cash

: $12.88 Mil (TTM As of Dec. 2023)
View and export this data going back to 2015. Start your Free Trial

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

aTyr Pharma's Net Change in Cash for the three months ended in Dec. 2023 was $12.79 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was $12.88 Mil.

aTyr Pharma Net Change in Cash Historical Data

The historical data trend for aTyr Pharma's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => -13.75 [6] => 7.74 [7] => -14.62 [8] => 10.81 [9] => 12.88 )
aTyr Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
 Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.75 7.74 -14.62 10.81 12.88

aTyr Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Change in Cash Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.45 10.73 -8.15 -2.49 12.79

aTyr Pharma Net Change in Cash Calculation

aTyr Pharma's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-33.221+-20.127+66.23+0
=12.88

aTyr Pharma's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-11.062+17.818+6.034+0
=12.79

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

aTyr Pharma Net Change in Cash Related Terms

Thank you for viewing the detailed overview of aTyr Pharma's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

aTyr Pharma (aTyr Pharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » aTyr Pharma Inc (NAS:LIFE) » Definitions » Net Change in Cash
Comparable Companies
ELYM CAPR OMER STTK NGM BCAB NKGN CLDI ANVS CDTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
471A:Germany
Address
10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
Website
https://www.atyrpharma.com
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Executives
Sanjay Shukla officer: Chief Medical Officer C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO CA 92121
Paul Schimmel director 88 SIDNEY ST, CAMBRIDGE MA 02139
Jill Marie Broadfoot officer: Chief Financial Officer 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Sara Zaknoen director C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
John K Clarke director C/O CARDINAL HEALTH PARTNERS, 221 NASSAU STREET, PRINCETON NJ 08542
Nancy Krueger officer: See Remarks C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Svetlana Lucas director 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Jane A Gross director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
John Mendlein director, officer: CEO and Executive Chairman
Ecor1 Capital Fund Qualified, L.p. 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ashraf Amanullah officer: Vice President, Manufacturing C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
John T Blake officer: Vice President, Finance C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342
Timothy P Coughlin director 339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075
Jeffrey S. Hatfield director 11080 ROSELLE STREET, SAN DIEGO CA 92121
David John King officer: See Remarks 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121

aTyr Pharma (aTyr Pharma) Headlines

From GuruFocus

aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution

By sperokesalga sperokesalga • 03-21-2023

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Value_Insider Value_Insider • 11-18-2022

aTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 2023 International Conference

By Stock market mentor Stock market mentor • 01-31-2023

aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment

By Value_Insider Value_Insider • 12-15-2022

aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update

By Marketwired • 08-09-2023

aTyr Pharma to Present at November Investor Conferences

By Marketwired • 11-01-2023

aTyr Pharma Announces First Major Review Article for Efzofitimod Published in the Journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases

By sperokesalga sperokesalga • 03-30-2023

aTyr Pharma Announces Commencement of Public Offering of Common Stock

By sperokesalga sperokesalga • 02-08-2023

European Commission Grants Orphan Drug Designation for aTyr Pharma's Efzofitimod for Treatment of Sarcoidosis

By Stock market mentor Stock market mentor • 01-18-2023

aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis

By Stock market mentor Stock market mentor • 01-19-2023